pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx patents
0 pharmaceutical patents indexed for Argenx. 0 expire within 24 months.
Argenx has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Argenx have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Argenx patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.